CA2474590A1 - Traitement de troubles fonctionnels sexuels masculins - Google Patents

Traitement de troubles fonctionnels sexuels masculins Download PDF

Info

Publication number
CA2474590A1
CA2474590A1 CA002474590A CA2474590A CA2474590A1 CA 2474590 A1 CA2474590 A1 CA 2474590A1 CA 002474590 A CA002474590 A CA 002474590A CA 2474590 A CA2474590 A CA 2474590A CA 2474590 A1 CA2474590 A1 CA 2474590A1
Authority
CA
Canada
Prior art keywords
oxytocin
selective
receptors
receptor
vasopressin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002474590A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Rachel Jane Russell
Stephen Derek Albert Street
Kim-Wah Tang
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2474590A1 publication Critical patent/CA2474590A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composition comprenant un antagoniste d'ocytocine sélectif destiné au traitement et/ou à la prévention des troubles de l'éjaculation, dans lequel on mélange éventuellement un antagoniste d'ocytocine sélectif avec un porteur, un diluant ou un excipient répondant aux normes pharmaceutiques.
CA002474590A 2002-01-31 2003-01-20 Traitement de troubles fonctionnels sexuels masculins Abandoned CA2474590A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
GB0202282.0 2002-01-31
PCT/IB2003/000140 WO2003064402A1 (fr) 2002-01-31 2003-01-20 Traitement de troubles fonctionnels sexuels masculins

Publications (1)

Publication Number Publication Date
CA2474590A1 true CA2474590A1 (fr) 2003-08-07

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002474590A Abandoned CA2474590A1 (fr) 2002-01-31 2003-01-20 Traitement de troubles fonctionnels sexuels masculins

Country Status (16)

Country Link
EP (1) EP1470115A1 (fr)
JP (3) JP2005525321A (fr)
KR (2) KR100829262B1 (fr)
CN (1) CN100500658C (fr)
AU (1) AU2003201471B2 (fr)
BR (1) BR0307337A (fr)
CA (1) CA2474590A1 (fr)
GB (1) GB0202282D0 (fr)
HK (1) HK1073109A1 (fr)
IL (2) IL162822A0 (fr)
MX (1) MXPA04007434A (fr)
NZ (1) NZ546408A (fr)
PL (1) PL371415A1 (fr)
TW (1) TW200302732A (fr)
WO (1) WO2003064402A1 (fr)
ZA (1) ZA200405208B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (fr) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Traitement et prévention de l'éjaculation précoce (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
CA2151821A1 (fr) * 1992-12-23 1994-07-07 Kevin Gilbert Derives de substitution hydantoine et succinimide d'antagonistes de spiro-indanylcamphresulfonyle oxytocine
CA2118756A1 (fr) * 1993-03-12 1994-09-13 Anthony M. Demarco Methode de synthese de derives de substitution amidiques d'antagonistes de la piperizinylcamphresulfonyloxytocine
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
TW200302732A (en) 2003-08-16
KR20040079958A (ko) 2004-09-16
HK1073109A1 (en) 2005-09-23
GB0202282D0 (en) 2002-03-20
ZA200405208B (en) 2005-08-31
NZ546408A (en) 2007-10-26
IL162822A (en) 2010-11-30
CN1625553A (zh) 2005-06-08
KR20080011232A (ko) 2008-01-31
BR0307337A (pt) 2004-12-07
JP2010209075A (ja) 2010-09-24
JP2005525321A (ja) 2005-08-25
IL162822A0 (en) 2005-11-20
CN100500658C (zh) 2009-06-17
KR100829262B1 (ko) 2008-05-13
PL371415A1 (en) 2005-06-13
JP2013151511A (ja) 2013-08-08
EP1470115A1 (fr) 2004-10-27
MXPA04007434A (es) 2004-10-11
WO2003064402A1 (fr) 2003-08-07
AU2003201471B2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
JP2004502735A (ja) 男性の性機能障害の治療
JP2005350482A (ja) Ｆｓｄの処置のための化合物
US20030119714A1 (en) Treatment of male sexual dysfunction
JP2008266338A (ja) 性機能障害を治療するための選択的ドーパミンｄ３受容体アゴニスト
US20150072995A1 (en) Treatment of male sexual dysfunction
JP2004522720A (ja) 雄性性的機能障害の処置
AU2003201471B2 (en) Treatment of male sexual dysfunction
AU2003201471A1 (en) Treatment of male sexual dysfunction
JP2004517046A (ja) 医薬
US20040185094A1 (en) Pharmaceutical
KR20030061441A (ko) 남성 성기능 장애의 치료
ZA200304460B (en) Treatment of male sexual dysfunction.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued